[Pharmacokinetics of cefuroxime in pregnant women with acute pyelonephritis]

Related Experiment Video

Updated: Oct 27, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

Z M Akhtamova, L E Khokholov, V V Dorokhov

    Antibiotiki I Meditsinskaia Biotekhnologiia = Antibiotics and Medical Biotechnology
    |February 1, 1985
    PubMed

    The pharmacokinetics of cefuroxime was studied in 40 pregnant women with acute pyelonephritis. The women were in the 2nd and 3rd terms of pregnancy. The antibiotic was injected in a dose of 500 mg. The antibiotic levels in the blood and urine were determined with the agar diffusion method. The pharmacokinetic parameters were measured in a one-compartmental model with regard to antibiotic absorption. The measurement was performed with the use of computer. The cefuroxime concentrations in the blood and urine were practically the same at all periods of the study and at different terms of pregnancy. In pregnant women with acute pyelonephritis, the volume of cefuroxime distribution and the time of a two-fold decrease in the blood antibiotic levels increased. The estimation of the optimal scheme of cefuroxime dosing by the Krueger-Timer principles provided treatment of acute pyelonephritis in pregnant women with intramuscular injections of the antibiotic in a dose of 500 mg every 8 hours for 7-8 days.

    More Related Videos

    Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice04:18

    Modeling Ascending Vaginal Infection, Preterm Birth, and Neonatal Morbidity in Mice

    Published on: October 10, 2025

    Related Concept Videos

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

    Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Acute Pyelonephritis I: Introduction01:27

    Acute Pyelonephritis I: Introduction

    Pyelonephritis is a bacterial infection that primarily affects the renal parenchyma and collecting system, including the renal pelvis, tubules, and interstitial tissue of one or both kidneys. It can be classified as either acute—a sudden, severe infection—or chronic, which refers to long-term or recurrent kidney infections.The primary cause of acute pyelonephritis (APN) is bacterial infection, with Escherichia coli accounting for approximately 70-80% of cases. Other bacteria, such as Proteus,...
    Acute Pyelonephritis II: Diagnostic Studies and Management01:28

    Acute Pyelonephritis II: Diagnostic Studies and Management

    Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...